Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Monday, 31 July 2017

MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test

MDxHealth (R)    

Published: 07:00 CEST 31-07-2017 /GlobeNewswire /Source: MDxHealth (R) / : MDXH /ISIN: BE0003844611

MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test


IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST- July 31, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that MVZ Dr. Stein & Kollegen medical laboratory has signed an agreement to become the first German laboratory  to offer the SelectMDx for Prostate Cancer test.


Under the terms of the agreement, MVZ Dr. Stein & Kollegen medical laboratory in Mönchengladbach Germany, one of the laboratories within the Limbach Gruppe SE, will perform SelectMDx service testing. To offer this service through their network, the laboratory  will purchase SelectMDx CE-marked IVD kits from MDxHealth.


"We are excited that   MVZ Dr. Stein & Kollegen lab is the first medical laboratory in Germany to offer SelectMDx service testing to their customers," said Dr. Jan Groen, CEO of MDxHealth. " Their broad hospital network and commercial capabilities will significantly contribute to the successful market penetration of SelectMDx."


"We are excited to partner with MDxHealth and provide this new innovative liquid biopsy test for all our patients within our laboratory service network in Germany," stated Dr. Dietmar Dreßen, General Manager of MVZ Stein & Kollegen. "By offering this non-invasive test we expect to optimize prostate cancer diagnosis and management."


About SelectMDx for Prostate Cancer

Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. SelectMDx helps identify men at increased risk of harboring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce unnecessary MRI procedures and invasive prostate biopsies by up to 50%, thereby reducing healthcare costs.


About MVZ Dr. Stein & Kollegen

MVZ Stein & Kollegen medical laboratory in Mönchengladbach is one of the largest laboratory of the Limbach Gruppe SE. The laboratory performs over 350,000 analyses per day from more than 20,000 patients.  MVZ Stein & Kollegen have  over 30 years of experience in laboratory diagnostics providing the highest and quality service to their doctors and patients. For more information, www.labor-stein.de.



About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.


For more information:


Shalon Roth

Dr. Dietmar Dreßen

EVP Corporate Communications MDxHealth

General Manager of MVZ Stein & Kollegen

+44 (0)7393 906278

+49 (0) 2161 8194 0





This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.  This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.


NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.




Click here for pdf

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: MDxHealth (R), Rue d'Abhooz, 31, Herstal 4040, Belgique
If you would like to unsubscribe and stop receiving these e-mails click here.